Janux Therapeutics Future Growth
Future criteria checks 2/6
Janux Therapeutics's earnings are forecast to decline at 14.8% per annum while its annual revenue is expected to grow at 62.7% per year. EPS is expected to decline by 8.4% per annum.
Key information
-14.8%
Earnings growth rate
-8.4%
EPS growth rate
| Biotechs earnings growth | 24.1% |
| Revenue growth rate | 62.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 11 | -121 | -105 | -60 | 6 |
| 12/31/2025 | 2 | -95 | -92 | -51 | 7 |
| 12/31/2024 | 3 | -73 | -21 | 9 | 7 |
| 12/31/2023 | 8 | -58 | -52 | -51 | N/A |
| 9/30/2023 | 8 | -63 | -56 | -53 | N/A |
| 6/30/2023 | 8 | -68 | -60 | -54 | N/A |
| 3/31/2023 | 9 | -67 | -51 | -45 | N/A |
| 12/31/2022 | 9 | -63 | -49 | -43 | N/A |
| 9/30/2022 | 7 | -60 | -47 | -41 | N/A |
| 6/30/2022 | 7 | -54 | -37 | -34 | N/A |
| 3/31/2022 | 5 | -44 | -36 | -34 | N/A |
| 12/31/2021 | 4 | -33 | -18 | -17 | N/A |
| 9/30/2021 | 2 | -21 | -8 | -8 | N/A |
| 6/30/2021 | 1 | -11 | -4 | -3 | N/A |
| 3/31/2021 | 0 | -8 | 2 | 2 | N/A |
| 12/31/2020 | N/A | -7 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JANX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JANX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JANX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JANX's revenue (62.7% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: JANX's revenue (62.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if JANX's Return on Equity is forecast to be high in 3 years time